Therapeutic Research

Abstract

We investigated the effects of the angiotensin I I receptor blocker olmesartan oninsulin resistance in 14 hypertensive patients with obesity（6 men, 8 women；mean age 50.7±6.9 years, mean BMI 28.8±2.1, mean±SD）. All subjects were treated with 20 mg of olmesartan for 3 to 5 months. BMI, blood pressure（BP）, heart rate（HR）, fasting plasma glucose（FPG）, fasting serum immunoreactive insulin（F－IRI）, HbA1c（NGSP）, insulin resistance index as assessed by homeostasis model assessment（HOMA－R）, serum adiponectin, plasma renin activity（PRA）and serum aldosterone were measured before and after 3 to 5 months of treatment. Olmesartan treatment lowered BP, F－IRI, HOMA－R andserum aldosterone and increased serum adiponectin and PRA significantly. No clinically significant changes in BMI, HR, FPG and HbA1c were observed during treatment. We conclude that olmesartan improves insulin resistance in hypertensive patients with obesity.